Worth reading
70In focus
Scored from 3 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
899
¥100 million (year-on-year increase in operating profit)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportFirst quarter of the fiscal year ending March 20276 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales6,409 Hundreds of millions of yen+26.7%
Operating profit1,845 Hundreds of millions of yen+94.9%
Ordinary income¥1,865 100 million +106.3%pre-tax quarterly profit, IFRS
Net income¥1,418 100 million +107.2%profit for the quarter
Selling, general and administrative expenses2,151 Hundreds of millions of yen
Operating profit margin
Rate28.8%
Year-on-year change (points)Improved by 10.1 percentage points (18.7% in the year-earlier period)
Results for the three months of the current quarterRevenue of ¥640.9 billion, operating profit of ¥184.5 billion, pre-tax quarterly profit of ¥186.5 billion, and quarterly profit of ¥141.8 billion (up 26.7%, 94.9%, 106.3%, and 107.2%, respectively, year on year)
Full-year earnings forecast
Revenue
22,200 Hundreds of millions of yen
Operating profit
3,950 Hundreds of millions of yen
Profit before tax
3,850 Hundreds of millions of yen
Quarterly profit
3,000 Hundreds of millions of yen
Core operating profit
6,200 Hundreds of millions of yen
Core quarterly profit
4,600 Hundreds of millions of yen
Capital expenditures
550 Hundreds of millions of yen
Research and development costs
3,550 Hundreds of millions of yen
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Changes in Exchange Rates
Revenue
600 Hundreds of millions of yen
Core operating profit
255 Hundreds of millions of yen
Increase in costs of sales
279 Hundreds of millions of yen
Increase in SG&A expenses
181 Hundreds of millions of yen
Increase in R&D expenses
100 Hundreds of millions of yen
Decrease in impairment losses on intangible assets
135 Hundreds of millions of yen
Decrease in other expenses
170 Hundreds of millions of yen
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
USD/JPY150
EUR/JPY180
New initiatives
- European approval for PADCEV, filings in Japan and China, and U.S. approval for PADCEV
- Launch of a Phase 3 trial of PADCEV for bladder-preserving therapy
- Filing for IZERVAY in China
Key KPIsA metric the company considers important as a management benchmark.
- Total sales of key strategic products1,603 Hundreds of millions of yenYear on year against the same period last yearUp 43.2% year on year
- XTANDI revenue2,766 Hundreds of millions of yenYear on year against the same period last yearUp 18.7% year on year
- PADCEV revenue755 Hundreds of millions of yenYear on year against the same period last yearUp 36.0% year on year
- IZERVAY revenue272 Hundreds of millions of yenYear on year against the same period last yearUp 70.3% year on year
- VYLOY revenue211 Hundreds of millions of yenYear on year against the same period last yearUp 50.7% year on year
- VEOZAH revenue149 Hundreds of millions of yenYear on year against the same period last yearUp 54.8% year on year
- XOSPATA revenue216 Hundreds of millions of yenYear on year against the same period last yearUp 27.3% year on year
- Betanis / Myrbetriq / Betmiga sales634 Hundreds of millions of yenYear on year against the same period last yearUp 47.5% year on year
- Prograf revenue585 Hundreds of millions of yenYear on year against the same period last yearUp 14.2% year on year
Segment results
United States
Sales
2,888 Hundreds of millions of yen+28.5%
Japan
Sales
796 Hundreds of millions of yen+15.5%
Established Markets
Sales
1,522 Hundreds of millions of yen+18.2%
China
Sales
321 Hundreds of millions of yen+8.9%
International Markets
Sales
854 Hundreds of millions of yen+60.5%
Capital expenditures
¥101 100 million first quarter
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | 6,409 Hundreds of millions of yen (YoY +26.7%) |
| Operating profit | 1,845 Hundreds of millions of yen (YoY +94.9%) |
| Ordinary income | ¥1,865 100 million (pre-tax quarterly profit, IFRS) (YoY +106.3%) |
| Net income | ¥1,418 100 million (profit for the quarter) (YoY +107.2%) |
| Operating profit margin | Rate 28.8% / Year-on-year change (points) Improved by 10.1 percentage points (18.7% in the year-earlier period) |
| Selling, general and administrative expenses | 2,151 Hundreds of millions of yen |
| Results for the three months of the current quarter | Revenue of ¥640.9 billion, operating profit of ¥184.5 billion, pre-tax quarterly profit of ¥186.5 billion, and quarterly profit of ¥141.8 billion (up 26.7%, 94.9%, 106.3%, and 107.2%, respectively, year on year) |
| Full-year earnings forecast | Revenue 22,200 Hundreds of millions of yen / Operating profit 3,950 Hundreds of millions of yen / Profit before tax 3,850 Hundreds of millions of yen / Quarterly profit 3,000 Hundreds of millions of yen / Core operating profit 6,200 Hundreds of millions of yen / Core quarterly profit 4,600 Hundreds of millions of yen / Capital expenditures 550 Hundreds of millions of yen / Research and development costs 3,550 Hundreds of millions of yen |
| Segment results | United States Sales 2,888 Hundreds of millions of yen (YoY +28.5%) / Profit Not disclosed / Japan Sales 796 Hundreds of millions of yen (YoY +15.5%) / Profit Not disclosed / Established Markets Sales 1,522 Hundreds of millions of yen (YoY +18.2%) / Profit Not disclosed / China Sales 321 Hundreds of millions of yen (YoY +8.9%) / Profit Not disclosed / International Markets Sales 854 Hundreds of millions of yen (YoY +60.5%) / Profit Not disclosed |
| Breakdown of Factors Affecting the Change | Changes in Exchange Rates Revenue 600 Hundreds of millions of yen / Core operating profit 255 Hundreds of millions of yen / Increase in costs of sales 279 Hundreds of millions of yen / Increase in SG&A expenses 181 Hundreds of millions of yen / Increase in R&D expenses 100 Hundreds of millions of yen / Decrease in impairment losses on intangible assets 135 Hundreds of millions of yen / Decrease in other expenses 170 Hundreds of millions of yen |
| Key KPIs | Indicator name Total sales of key strategic products / Value 1,603 Hundreds of millions of yen / Year on year against the same period last year Up 43.2% year on year, Indicator name XTANDI revenue / Value 2,766 Hundreds of millions of yen / Year on year against the same period last year Up 18.7% year on year, Indicator name PADCEV revenue / Value 755 Hundreds of millions of yen / Year on year against the same period last year Up 36.0% year on year, Indicator name IZERVAY revenue / Value 272 Hundreds of millions of yen / Year on year against the same period last year Up 70.3% year on year, Indicator name VYLOY revenue / Value 211 Hundreds of millions of yen / Year on year against the same period last year Up 50.7% year on year, Indicator name VEOZAH revenue / Value 149 Hundreds of millions of yen / Year on year against the same period last year Up 54.8% year on year, Indicator name XOSPATA revenue / Value 216 Hundreds of millions of yen / Year on year against the same period last year Up 27.3% year on year, Indicator name Betanis / Myrbetriq / Betmiga sales / Value 634 Hundreds of millions of yen / Year on year against the same period last year Up 47.5% year on year, Indicator name Prograf revenue / Value 585 Hundreds of millions of yen / Year on year against the same period last year Up 14.2% year on year |
| Assumptions Underlying the Business Outlook | USD/JPY 150 / EUR/JPY 180 |
| Capital expenditures | ¥101 100 million (first quarter) |
| New initiatives | European approval for PADCEV, filings in Japan and China, and U.S. approval for PADCEV, Launch of a Phase 3 trial of PADCEV for bladder-preserving therapy, Filing for IZERVAY in China |
Items this document does not state (15)
Gross Profit MarginProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company states that changes in foreign exchange rates increased revenue by ¥60 billion and core operating profit by ¥25.5 billion. In addition, impairment losses on intangible assets, which amounted to ¥13.6 billion in the year-earlier period, were zero in the current period, while other expenses decreased by ¥17 billion.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.